Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow), page-51

The other indications - Parkinson's et al are just a teaser. MT has admitted we won't get far down the road with these as we will be sold if the ALS treatment works out. It always worries me when the market doesn't see what I see; as evidenced by the moribund share price. In valuing the company based on ALS success, the only variable is the risk of failure. At present the market is weighting the chance of FDA approval at between 3-5%. The question is why? I guess it could be lack of awareness or perhaps a lack of trust in the data due to small study size. The OLE is critical in maintaining SP momentum. Without continuing good results, I see the chance the chance of a buyout before the 24 week print as close to zero. However, if the OLE demonstrates a substantial slowing of disease progression and excellent survival rates then FOMO will kick in big time and BP will act quickly. Therefore I believe the next great inflection point is the release of the OLE results.